Skip to main content
Erschienen in: Pediatric Cardiology 6/2007

01.11.2007

Medical Management of the Failing Fontan

verfasst von: N. S. Ghanayem, S. Berger, J. S. Tweddell

Erschienen in: Pediatric Cardiology | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

The Fontan operation accomplishes complete separation of systemic venous blood from pulmonary venous circulation in patients with single ventricle anatomy. Operative survival since the first description of the Fontan operation is excellent in the current era through modifications in surgical techniques, identification of patient-specific risk factors, and advances in postoperative care. Improved early outcomes have also resulted in a decline in late mortality for patients who have undergone staged palliation with the Fontan operation. As the number of late survivors from the Fontan operation increases, caregivers will be evermore faced with the challenge of recognizing and managing the patient with failing Fontan physiology. Even after excellent early results, patients with single ventricle lesions remain at risk of progressive ventricular dysfunction, dysrhythmias, progressive hypoxemia, elevated pulmonary vascular resistance, and protein-losing enteropathy, which can result in morbidities including but not limited to, myocardial failure, thromboembolism, and stroke. Consequently, continued long-term survival of patients who undergo the Fontan operation is dependent upon preservation of single ventricle function, avoidance of late complications, and, in the patient with a failing Fontan, recognition and treatment of the underlying pathophysiologic process that has resulted in Fontan failure.
Literatur
1.
Zurück zum Zitat Bendayan I, Casaldaliga J, Castello F, et al. (2000) Heparin therapy and reversal of protein-losing enteropathy in a case with congenital heart disease. Pediatr Cardiol 21:267–268PubMedCrossRef Bendayan I, Casaldaliga J, Castello F, et al. (2000) Heparin therapy and reversal of protein-losing enteropathy in a case with congenital heart disease. Pediatr Cardiol 21:267–268PubMedCrossRef
2.
Zurück zum Zitat Border WL, Syed AU, Michelfelder EC, et al. (2003) Impaired systemic ventricular relaxation affects postoperative short-term outcome in Fontan patients. J Thorac Cardiovasc Surg 126:1760–1764PubMedCrossRef Border WL, Syed AU, Michelfelder EC, et al. (2003) Impaired systemic ventricular relaxation affects postoperative short-term outcome in Fontan patients. J Thorac Cardiovasc Surg 126:1760–1764PubMedCrossRef
3.
Zurück zum Zitat Bruns LA, Chrisant MK, Lamour JM, et al. (2001) Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138:505–511PubMedCrossRef Bruns LA, Chrisant MK, Lamour JM, et al. (2001) Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. J Pediatr 138:505–511PubMedCrossRef
4.
Zurück zum Zitat Burkhart HM, Dearani JA, Mair DD, et al. (2003) The modified Fontan procedure: early and late results in 132 adults. J Thorac Cardiovasc Surg 125:1252–1259PubMedCrossRef Burkhart HM, Dearani JA, Mair DD, et al. (2003) The modified Fontan procedure: early and late results in 132 adults. J Thorac Cardiovasc Surg 125:1252–1259PubMedCrossRef
5.
Zurück zum Zitat Cesario D, Clark J, Maisel A (1998) Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 135:121–129PubMedCrossRef Cesario D, Clark J, Maisel A (1998) Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 135:121–129PubMedCrossRef
6.
Zurück zum Zitat Chakrabarti S, Keeton BR, Salmon AP, et al. (2003) Acquired combined immunodeficiency associated with protein losing enteropathy complicating Fontan operation. Heart 89:1130–1131PubMedCrossRef Chakrabarti S, Keeton BR, Salmon AP, et al. (2003) Acquired combined immunodeficiency associated with protein losing enteropathy complicating Fontan operation. Heart 89:1130–1131PubMedCrossRef
7.
Zurück zum Zitat Cheung YF, Penny DJ, Redington AN (2000) Serial assessment of left ventricular diastolic function after Fontan procedure. Heart 83:420–424PubMedCrossRef Cheung YF, Penny DJ, Redington AN (2000) Serial assessment of left ventricular diastolic function after Fontan procedure. Heart 83:420–424PubMedCrossRef
8.
Zurück zum Zitat Donnelly JP, Rosenthal A, Castle VP, et al. (1997) Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 130:474–478PubMedCrossRef Donnelly JP, Rosenthal A, Castle VP, et al. (1997) Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 130:474–478PubMedCrossRef
9.
Zurück zum Zitat Driscoll DJ, Offord KP, Feldt RH, et al. (1992) Five- to fifteen-year follow-up after Fontan operations. Circulation 85:469–496PubMed Driscoll DJ, Offord KP, Feldt RH, et al. (1992) Five- to fifteen-year follow-up after Fontan operations. Circulation 85:469–496PubMed
10.
Zurück zum Zitat Feldt RH, Driscoll DJ, Offord KP, et al. (1996) Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 112:672–680PubMedCrossRef Feldt RH, Driscoll DJ, Offord KP, et al. (1996) Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 112:672–680PubMedCrossRef
11.
Zurück zum Zitat Fonarow G (2003) B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure. Heart Failure Rev 8:321–325CrossRef Fonarow G (2003) B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure. Heart Failure Rev 8:321–325CrossRef
12.
Zurück zum Zitat Gentles TL, Gauvreau K, Mayer JE, et al. (1997) Functional outcome after the Fontan operation: factors influencing late morbidity. J Thorac Cardiovasc Surg 114:392–403PubMedCrossRef Gentles TL, Gauvreau K, Mayer JE, et al. (1997) Functional outcome after the Fontan operation: factors influencing late morbidity. J Thorac Cardiovasc Surg 114:392–403PubMedCrossRef
13.
Zurück zum Zitat Gewillig M (1994) The Fontan circulation: late functional results. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 6:56–63 Gewillig M (1994) The Fontan circulation: late functional results. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 6:56–63
14.
Zurück zum Zitat Hennein HA (2002) The Fontan operation for hypoplastic left heart syndrome. In: Hennein HA, Bove EL (eds) Hypoplastic Left Heart Syndrome 2002. Futura, New York, pp 155–178 Hennein HA (2002) The Fontan operation for hypoplastic left heart syndrome. In: Hennein HA, Bove EL (eds) Hypoplastic Left Heart Syndrome 2002. Futura, New York, pp 155–178
15.
Zurück zum Zitat Heragu N, Mahony L (1999) Is captopril useful in decreasing pleural drainage in children after modified Fontan operation. Am J Cardiol 84:1109–1112PubMedCrossRef Heragu N, Mahony L (1999) Is captopril useful in decreasing pleural drainage in children after modified Fontan operation. Am J Cardiol 84:1109–1112PubMedCrossRef
16.
Zurück zum Zitat Hjortdal VE, Stenberg EV, Ravn HB, et al. (2000) Neurohumoral activation late after cavopulmonary connection. Heart 83:439–443PubMedCrossRef Hjortdal VE, Stenberg EV, Ravn HB, et al. (2000) Neurohumoral activation late after cavopulmonary connection. Heart 83:439–443PubMedCrossRef
17.
Zurück zum Zitat Hoffman TM, Wernovsky G, Atz AM, et al. (2003) Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107:996–1002PubMedCrossRef Hoffman TM, Wernovsky G, Atz AM, et al. (2003) Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107:996–1002PubMedCrossRef
18.
Zurück zum Zitat Jacobs ML, Rychik J, Byrum CJ, et al. (1996) Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg 61:206–208PubMedCrossRef Jacobs ML, Rychik J, Byrum CJ, et al. (1996) Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg 61:206–208PubMedCrossRef
19.
Zurück zum Zitat Khambadkone S, Li J, de Leval MR, et al. (2003) Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 107:3204–3208PubMedCrossRef Khambadkone S, Li J, de Leval MR, et al. (2003) Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 107:3204–3208PubMedCrossRef
20.
Zurück zum Zitat Kim S, In-Seung P, Song J, et al. (2004) Reversal of protein-losing enteropathy with calcium replacement in a patient after Fontan operation. Ann Thorac Surg 77:1456–1457PubMedCrossRef Kim S, In-Seung P, Song J, et al. (2004) Reversal of protein-losing enteropathy with calcium replacement in a patient after Fontan operation. Ann Thorac Surg 77:1456–1457PubMedCrossRef
21.
Zurück zum Zitat Knott-Craig CJ, Danielson GK, Schaff HV, et al. (1995) The modified Fontan operation: an analysis of risk factors for early postoperative death or takedown in 702 consecutive patients from one institution. J Thorac Cardiovasc Surg 109:1237–1243PubMedCrossRef Knott-Craig CJ, Danielson GK, Schaff HV, et al. (1995) The modified Fontan operation: an analysis of risk factors for early postoperative death or takedown in 702 consecutive patients from one institution. J Thorac Cardiovasc Surg 109:1237–1243PubMedCrossRef
22.
Zurück zum Zitat Kukin ML (2002) β-Blockers in chronic heart failure: considerations for selecting an agent. Mayo Clinic Proc 77:1199–1206CrossRef Kukin ML (2002) β-Blockers in chronic heart failure: considerations for selecting an agent. Mayo Clinic Proc 77:1199–1206CrossRef
23.
Zurück zum Zitat Lenz D, Hambsch J, Schneider P, et al. (2003) Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? Crit Care 7:185–190PubMedCrossRef Lenz D, Hambsch J, Schneider P, et al. (2003) Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? Crit Care 7:185–190PubMedCrossRef
24.
Zurück zum Zitat Levy M, Danel C, Laval A, et al. (2003) Nitric oxide synthase expression by pulmonary arteries: a predictive marker of Fontan procedure outcome? J Thorac Cardiovasc Surg 125:1083–1090PubMedCrossRef Levy M, Danel C, Laval A, et al. (2003) Nitric oxide synthase expression by pulmonary arteries: a predictive marker of Fontan procedure outcome? J Thorac Cardiovasc Surg 125:1083–1090PubMedCrossRef
25.
Zurück zum Zitat Lopez-Candales A, Vora T, Gibbons W, et al. (2002) Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controlled pilot study. J Med 33:129–146PubMed Lopez-Candales A, Vora T, Gibbons W, et al. (2002) Symptomatic improvement in patients treated with intermittent infusion of inotropes: a double-blind placebo controlled pilot study. J Med 33:129–146PubMed
26.
Zurück zum Zitat Mahle WT, Coon PD, Wernovsky G, et al. (2001) Quantitative echocardiographic assessment of the performance of the functionally single right ventricle after the Fontan operation. Cardiol Young 11:399–406PubMedCrossRef Mahle WT, Coon PD, Wernovsky G, et al. (2001) Quantitative echocardiographic assessment of the performance of the functionally single right ventricle after the Fontan operation. Cardiol Young 11:399–406PubMedCrossRef
27.
Zurück zum Zitat Mainwaring RD, Lamberti JJ, Carter TL, et al. (1995) Renin, angiotensin II, and the development of effusions following bidirectional Glenn and Fontan procedures. J Card Surg 10:111–118PubMedCrossRef Mainwaring RD, Lamberti JJ, Carter TL, et al. (1995) Renin, angiotensin II, and the development of effusions following bidirectional Glenn and Fontan procedures. J Card Surg 10:111–118PubMedCrossRef
28.
Zurück zum Zitat Mair DD, Hagler DJ, Puga FJ, et al. (1992) Fontan operation in 176 patients with tricuspid atresia. Results and a proposed new index for patient selection. Circulation 82(Suppl IV):IV-164–IV-169 Mair DD, Hagler DJ, Puga FJ, et al. (1992) Fontan operation in 176 patients with tricuspid atresia. Results and a proposed new index for patient selection. Circulation 82(Suppl IV):IV-164–IV-169
29.
Zurück zum Zitat Mair DD, Puga FJ, Danielson GK (2001) The Fontan procedure for tricuspid atresia: early and late results of a 25-year experience with 216 patients. J Am Coll Cardiol 37:933–939PubMedCrossRef Mair DD, Puga FJ, Danielson GK (2001) The Fontan procedure for tricuspid atresia: early and late results of a 25-year experience with 216 patients. J Am Coll Cardiol 37:933–939PubMedCrossRef
30.
31.
Zurück zum Zitat Marshall J, Berkenbosch JW, Russo P (2004) Preliminary experience with nesiritide in the pediatric population. J Intens Care Med 19:164–170CrossRef Marshall J, Berkenbosch JW, Russo P (2004) Preliminary experience with nesiritide in the pediatric population. J Intens Care Med 19:164–170CrossRef
32.
Zurück zum Zitat Merten L, Hagler DJ, Sauer U, et al. (1998) Protein losing enteropathy after the Fontan operation: an international multicenter study. J Thorac Cardiovasc Surg 115:1063–1073CrossRef Merten L, Hagler DJ, Sauer U, et al. (1998) Protein losing enteropathy after the Fontan operation: an international multicenter study. J Thorac Cardiovasc Surg 115:1063–1073CrossRef
33.
Zurück zum Zitat Murch SH, Winyard PJD, Koletzko S, et al. (1996) Congenital enterocyte heparan sulfate deficiency with massive albumin loss, secretory diarrhea, and malnutrition. Lancet 347:1299–1301PubMedCrossRef Murch SH, Winyard PJD, Koletzko S, et al. (1996) Congenital enterocyte heparan sulfate deficiency with massive albumin loss, secretory diarrhea, and malnutrition. Lancet 347:1299–1301PubMedCrossRef
34.
Zurück zum Zitat Ohuchi H, Hasegawa S, Yasuda K, et al. (2001) Severely impaired cardiac autonomic nervous activity after the Fontan operation. Circulation 104:1513–1518PubMedCrossRef Ohuchi H, Hasegawa S, Yasuda K, et al. (2001) Severely impaired cardiac autonomic nervous activity after the Fontan operation. Circulation 104:1513–1518PubMedCrossRef
35.
Zurück zum Zitat Pfeffer MA, Braunwald E, Moye LA, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 327:669–667PubMedCrossRef Pfeffer MA, Braunwald E, Moye LA, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med 327:669–667PubMedCrossRef
36.
Zurück zum Zitat Powell AJ, Gauvreau K, Jenkins KJ, et al. (2001) Perioperative risk factors for development of protein-losing enteropathy following a Fontan procedure. Am J Cardiol 88:1206–1209PubMedCrossRef Powell AJ, Gauvreau K, Jenkins KJ, et al. (2001) Perioperative risk factors for development of protein-losing enteropathy following a Fontan procedure. Am J Cardiol 88:1206–1209PubMedCrossRef
37.
Zurück zum Zitat Ringel RE, Peddy SB (2003) Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol 91:1031–1032PubMedCrossRef Ringel RE, Peddy SB (2003) Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. Am J Cardiol 91:1031–1032PubMedCrossRef
38.
Zurück zum Zitat Rothman A, Mayer JE, Freed MD (1987) Treatment of chronic pleural effusions after the Fontan procedure with prednisone. Am J Cardiol 60:408–409PubMedCrossRef Rothman A, Mayer JE, Freed MD (1987) Treatment of chronic pleural effusions after the Fontan procedure with prednisone. Am J Cardiol 60:408–409PubMedCrossRef
39.
Zurück zum Zitat Rychik J, Spray TL (2002) Strategies to treat protein-losing enteropathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 5:3–11PubMedCrossRef Rychik J, Spray TL (2002) Strategies to treat protein-losing enteropathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 5:3–11PubMedCrossRef
40.
Zurück zum Zitat Sensaki H, Masutani S, Kobayashi J, et al. (2002) Ventricular afterload and ventricular work in Fontan circulation: comparison with normal two-ventricle circulation and single-ventricle circulation with Blalock–Taussig shunts. Circulation 105:2885–2892CrossRef Sensaki H, Masutani S, Kobayashi J, et al. (2002) Ventricular afterload and ventricular work in Fontan circulation: comparison with normal two-ventricle circulation and single-ventricle circulation with Blalock–Taussig shunts. Circulation 105:2885–2892CrossRef
41.
Zurück zum Zitat Silverman A, Roy CC (1983) Protein-losing enteropathy. In: Silverman A, Roy CC, (eds) Pediatric Clinical Gastroenterology, 3rd edn. Mosby, St. Louis, pp 304–323 Silverman A, Roy CC (1983) Protein-losing enteropathy. In: Silverman A, Roy CC, (eds) Pediatric Clinical Gastroenterology, 3rd edn. Mosby, St. Louis, pp 304–323
42.
Zurück zum Zitat Sorenson GK, Ramamoorthy C, Lynn AM, et al. (1996) Hemodynamic effects of amrinone in children after Fontan surgery. Anesth Analg 82:241–246CrossRef Sorenson GK, Ramamoorthy C, Lynn AM, et al. (1996) Hemodynamic effects of amrinone in children after Fontan surgery. Anesth Analg 82:241–246CrossRef
43.
Zurück zum Zitat Stewart JM, Gewitz MH, Clark BJ, et al. (1991) The role of vasopressin and atrial natriuretic factor in postoperative fluid retention after the Fontan procedure. J Thorac Cardiovasc Surg 102:821–829PubMed Stewart JM, Gewitz MH, Clark BJ, et al. (1991) The role of vasopressin and atrial natriuretic factor in postoperative fluid retention after the Fontan procedure. J Thorac Cardiovasc Surg 102:821–829PubMed
44.
Zurück zum Zitat Stier CT Jr, Koenig S, Lee DY, et al. (2003) Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (inspra). Heart Dis 5:102–118PubMedCrossRef Stier CT Jr, Koenig S, Lee DY, et al. (2003) Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (inspra). Heart Dis 5:102–118PubMedCrossRef
45.
Zurück zum Zitat Therrien J, Webb GD, Gatzoulis MA (1999) Reversal of protein losing enteropathy with prednisone in adults with modified Fontan operations: long term palliation or bridge to cardiac transplantation? Heart 82:241–243PubMed Therrien J, Webb GD, Gatzoulis MA (1999) Reversal of protein losing enteropathy with prednisone in adults with modified Fontan operations: long term palliation or bridge to cardiac transplantation? Heart 82:241–243PubMed
46.
Zurück zum Zitat Zellers TM, Brown K (1996) Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol 17:115–117PubMedCrossRef Zellers TM, Brown K (1996) Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol 17:115–117PubMedCrossRef
Metadaten
Titel
Medical Management of the Failing Fontan
verfasst von
N. S. Ghanayem
S. Berger
J. S. Tweddell
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 6/2007
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-007-9007-0

Weitere Artikel der Ausgabe 6/2007

Pediatric Cardiology 6/2007 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.